A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-6325 in Hepatitis C Infected Male and Female Patients.

Trial Profile

A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-6325 in Hepatitis C Infected Male and Female Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs MK 6325 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Feb 2013 Actual initiation date changed from Apr 2011 to May 2011 as reported by ClinicalTrials.gov.
    • 01 May 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top